Lung cancer causes nearly 1.69 million deaths globally and 5-year survival rate is less than 20%. Several biomarkers have improved treatment selection and overall prognosis in lung cancer to some extent (JNCCN; 2017;15:504). However, clinical relevance of these biomarkers is limited to only a small percentage of patients. Hence, there is a need for an individulized tool that can accurately predict an individual’s response to a therapy, especially in scenarios where there is a choice of equivalent treatment regimens and no specific biomarkers.
CANscript™ effectively recreates a patient’s tumor microenvironment ex vivo by preserving the native contexture. The platform provides phenotypic assessment of response to the drug(s) tested for a given tumor and generates clinically relevant predictions for real-time treatment selection (Nat. Commun. 2014, 6:6169 ). We used this platform to assese phenotypic response of lung tumors.
Twenty-one lung cancer patient tumors were treated with one or more FDA approved regimens including targeted therapy and chemotherapy in CANscript platform. We did not observe any advantage of targeted therapy (EGFR, PD1 inhibitors) over chemotherapy. Six tumors, which were non-responders to gefitinib, were predicted responders to carboplatin/pemetrexed and/or carboplatin/docetaxel. Further, out of 4 gefitinib responders, 3 were predicted to respond to chemotherapies carboplatin/pemetrexed or carboplatin/docetaxel. Highest efficacy was observed in carboplatin/pemetrexed and carboplatin/docetaxel (47% and 46% respectively). 25% tumors treated with anti-PD1 responded to the therapy, matching the reported clinical response rate of anti-PD-1 therapy.
CANscript™ is used as an ex-vivo, personalized platform that can predict an individual’s response to various classes of anticancer drugs. The platform has been validated over a large number of clinical samples and the current study indicates that CANscript is a preferred platform for selecting individualized drug responses for treatment of lung cancer.udy indicates that CANscript is a preferred platform for selecting individualized drug responses for treatment of lung cancer.
Clinical trial identification
Legal entity responsible for the study
Mitra Biotech and Kidwai Memorial Institute of Oncology.
Has not received any funding.
G. Babu: Consultant: HCG Hospital, Mitra Biotech. All other authors have declared no conflicts of interest.